학술논문
Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology.
Document Type
Article
Author
Toumia, Iméne Ben; Bachetti, Tiziana; Chekir-Ghedira, Leila; Profumo, Aldo; Ponassi, Marco; Di Domizio, Alessandro; Izzotti, Alberto; Sciacca, Salvatore; Puglisi, Caterina; Forte, Stefano; Giuffrida, Raffaella; Colarossi, Cristina; Milardi, Danilo; Grasso, Giuseppe; Lanza, Valeria; Fiordoro, Stefano; Drago, Giacomo; Tkachenko, Kateryna; Cardinali, Barbara; Romano, Paolo
Source
Frontiers in Pharmacology; 2024, p1-17, 17p
Subject
Language
ISSN
16639812
Abstract
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)